ERBB2 and neoplasm: Dong and colleagues created a novel CAR-M by genetically modifying macrophages to express a HER2-FcεR1γ-CAR (HF-CAR), which specifically targeted HER2-positive GC and exhibited great synergistic effects in combination with oxaliplatin, leading to significant anti-tumor functions in mouse models (Dong et al., 2023).